$10.14
6.66% today
Nasdaq, Feb 28, 05:18 pm CET
ISIN
US45826J1051
Symbol
NTLA
Sector
Industry

Intellia Therapeutics, Inc. Stock price

$10.86
+0.31 2.94% 1M
-12.08 52.66% 6M
-0.80 6.86% YTD
-20.16 64.99% 1Y
-87.99 89.01% 3Y
-0.75 6.46% 5Y
-11.24 50.86% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.06 0.56%
ISIN
US45826J1051
Symbol
NTLA
Sector
Industry

Key metrics

Market capitalization $1.11b
Enterprise Value $549.59m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 12.75
P/S ratio (TTM) P/S ratio 25.67
P/B ratio (TTM) P/B ratio 1.15
Revenue growth (TTM) Revenue growth -16.77%
Revenue (TTM) Revenue $43.09m
EBIT (operating result TTM) EBIT $-537.71m
Free Cash Flow (TTM) Free Cash Flow $-363.06m
Cash position $658.11m
EPS (TTM) EPS $-5.45
P/E forward negative
P/S forward 20.40
EV/Sales forward 10.08
Short interest 26.90%
Show more

Is Intellia Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Intellia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Intellia Therapeutics, Inc. forecast:

18x Buy
75%
6x Hold
25%

Analyst Opinions

24 Analysts have issued a Intellia Therapeutics, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Intellia Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
43 43
17% 17%
100%
- Direct Costs 10 10
19% 19%
24%
33 33
24% 24%
76%
- Selling and Administrative Expenses 112 112
9% 9%
260%
- Research and Development Expense 448 448
7% 7%
1,040%
-528 -528
11% 11%
-1,224%
- Depreciation and Amortization 10 10
19% 19%
24%
EBIT (Operating Income) EBIT -538 -538
11% 11%
-1,248%
Net Profit -522 -522
13% 13%
-1,212%

In millions USD.

Don't miss a Thing! We will send you all news about Intellia Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Intellia Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
about 23 hours ago
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Brittany Chaves - Senior Manager of Investor Relations John Leonard - President and Chief Executive Officer David Lebwohl - Chief Medical Officer Edward Dulac - Executive Vice President and Chief Financial Officer Birgit Schultes - Executive Vice President and Chief Scie...
Positive
The Motley Fool
one day ago
Intellia Therapeutics (NTLA 8.52%), a leader in gene-editing technology, delivered its fourth-quarter earnings results on Feb. 27. The company reported a net loss of $1.27 per share, which was better than the $1.34 per share loss that analysts had expected, and revenue of $12.9 million, significantly outpacing the $7 million estimate.
Neutral
PRNewsWire
one day ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Intellia between July 30, 2024 and January 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 ...
More Intellia Therapeutics, Inc. News

Company Profile

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO John Leonard
Employees 526
Founded 2014
Website www.intelliatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today